BHV3241, verdiperstat

PreclinicalSmall molecule

BHV3241, verdiperstat is one of 14 small molecule programs targeting Multiple System Atrophy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple System AtrophyActive, not recruiting

Multiple System AtrophyPreclinical

Active, not recruiting

Competition

Competitive Landscape

20 competitors in Multiple System Atrophy

#DrugCompanyPhaseTrials

Rifadin

Northera

Sudafed

Rilutek

AAzurity Pharmaceuticals

Lu AF95245

1 6

TEV-56286

Teva

Phase 2

2 7

Foralumab

TTiziana Life Sciences LTD

Phase 2

1 8

Bendopa

MMerz North America, Inc.

Preclinical

1 9

ATH434

AAlterity Therapeutics

Phase 2

2 10

Human Dopaminergic Progenitor Cells

IiRegene Therapeutics Co., Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Multiple System Atrophy1 trial

Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)

No longer available·BBiohaven Pharmaceuticals, Inc.··NCT05086094

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BHV3241, verdiperstat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BHV3241, verdiperstat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BHV3241, verdiperstat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biohaven Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: BBiohaven Pharmaceuticals, Inc.

BHV3241, verdiperstat

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Multiple System Atrophy1 trial

References

Drug Info

Quick Facts

Related News